Relevant bibliographies by topics / Side effects of drugs

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Side effects of drugs'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Side effects of drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Side effects of drugs"

1

Garg, Pragati, and Swati Yadav. "OCULAR SIDE EFFECTS OF SYSTEMIC DRUGS." Era's Journal of Medical Research 6, no. 1 (June 2019): 54–62. http://dx.doi.org/10.24041/ejmr2019.111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Harrison, P. V. "Drugs and side-effects." Clinical and Experimental Dermatology 15, no. 1 (January 1990): 77–78. http://dx.doi.org/10.1111/j.1365-2230.1990.tb02034.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Eniu, Alexandra. "IN07 NEW DRUGS, NEW SIDE EFFECTS: ENDOCRINE SIDE EFFECTS." Breast 24 (November 2015): S23—S24. http://dx.doi.org/10.1016/s0960-9776(15)30020-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kuhn, Michael, Ivica Letunic, Lars Juhl Jensen, and Peer Bork. "The SIDER database of drugs and side effects." Nucleic Acids Research 44, no. D1 (October 19, 2015): D1075—D1079. http://dx.doi.org/10.1093/nar/gkv1075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Saltz, Bruce L., Margaret G. Woerner, Delbert G. Robinson, and John M. Kane. "Side effects of antipsychotic drugs." Postgraduate Medicine 107, no. 2 (January 2000): 169–78. http://dx.doi.org/10.3810/pgm.2000.02.891.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

GOIHMAN-YAHR, MAURICIO. "NEHUSHTAN: SIDE EFFECTS OF DRUGS." International Journal of Dermatology 32, no. 11 (November 1993): 790–91. http://dx.doi.org/10.1111/j.1365-4362.1993.tb02763.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

BARKIN, ROBERT L., and Z. L. G. STEIN. "Drugs With Anticholinergic Side Effects." Southern Medical Journal 82, no. 12 (December 1989): 1547. http://dx.doi.org/10.1097/00007611-198912000-00020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Makins, Richard, and Anne Ballinger. "Gastrointestinal side effects of drugs." Expert Opinion on Drug Safety 2, no. 4 (July 2003): 421–29. http://dx.doi.org/10.1517/14740338.2.4.421.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mohan, Alladi, and Surendra Kumar Sharma. "Side Effects of Antituberculosis Drugs." American Journal of Respiratory and Critical Care Medicine 169, no. 7 (April 2004): 882–83. http://dx.doi.org/10.1164/ajrccm.169.7.952.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lee, C. A., D. Mistry, S. Uppal, and A. P. Coatesworth. "Otologic side effects of drugs." Journal of Laryngology & Otology 119, no. 4 (April 2005): 267–71. http://dx.doi.org/10.1258/0022215054020485.

Full text
Abstract:
Otolaryngologic symptoms are common and patients presenting to the otolaryngologist will often be taking drugs for the treatment of unrelated diseases. As a doctor, one must not forget the potential of these drugs to cause otologic side effects and, in some cases, to be the cause of the presenting symptom.We performed a comprehensive search of the British National Formulary and Electronic Medical Compendium websites to classify the otologic side effects caused by drugs. Not all the data were found at both websites. We have compiled all the data together, subclassified them and produced a review of the otologic side effects of drugs, in table form.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Side effects of drugs"

1

Chu, Yu-Hsuan. "Custom Fluorophores for Investigating the Cellular Uptake Mechanisms and Side-Effects of Pharmaceuticals." PDXScholar, 2015. http://pdxscholar.library.pdx.edu/open_access_etds/2343.

Full text
Abstract:
There is a significant current need to elucidate the molecular mechanisms of the side-effects caused by widely-used pharmaceuticals. Examples include the acute nephrotoxicity and irreversible ototoxicity promoted by the cationic drugs gentamicin and cisplatin. Gentamicin is an aminoglycoside antibiotic used for the prevention and treatment of life-threatening gram-negative bacterial infections, such as tuberculosis and meningitis. Cisplatin is used to treat a broad spectrum of cancers including head and neck, ovarian, cervical, stomach, bladder, sarcoma, lymphoma, testicular cancer and others. The objective of this study is to design and synthesize rhodamine derivatives that can be used for the construction of geometrically well-defined cationic drug conjugates. The long-term goal is to use the conjugates as tools to aid in elucidating the properties and identities of ion channels involved in the uptake of cationic pharmaceuticals into kidney and cochlear hair cells. This will shed light on the origin and potential prevention of unwanted side effects such as nephrotoxicity and ototoxicity associated with specific cationic drugs. A series of extended rhodamine analogs with reactive groups for biomolecule conjugation has been synthesized. These fluorophores show similar spectral properties to their prototype, Texas Red succinimidyl ester (TR-SE). However, they contain rigid linkers between the fluorophore and amine-reactive moiety. The resultant gentamicin conjugates of these materials are rigidified enabling one to assess channel pore dimensions without the confounding issue of conjugate folding. Preliminary cell studies are promising, as one observes reduced gentamicin uptake in both kidney and sensory hair cell upon systematically increasing the dimension of the fluorophore. This work has enabled us to tentatively assign the maximum dilated MET channel pore size as between 1.44 nm to 1.56 nm. However, this preliminary finding, though encouraging, needs further validation via ongoing studies with larger diameter fluorophore conjugates, A cisplatin-Texas Red conjugate has also been synthesized to enable studies of cellular uptake mechanisms. This conjugate preserves not only the spectral properties of Texas Red after conjugation, but also the cytotoxicity of cisplatin. This has been validated in zebrafish. The series of rhodamine probes that have been conjugated to gentamicin should be similarly useful for cisplatin studies. These studies are planned. Additional future work includes the synthesis of semi-flexible (glycol) and flexible (alkyl) linkers to evaluate structure-activity relationships.
APA, Harvard, Vancouver, ISO, and other styles
2

Gharanei, A. M. "Investigation into the cardiotoxic effects of doxorubicin and strategies for cardioprotection." Thesis, Coventry University, 2013. http://curve.coventry.ac.uk/open/items/ad712004-828e-4d9a-8ddb-17951146d414/1.

Full text
Abstract:
Doxorubicin is one of the most effective anti-cancer agents; however its use is associated with adverse cardiac effects, including cardiomyopathy and progressive heart failure. Mitochondrial function and integrity are crucial for cellular processes in general and play an important role during diseased development. These characteristics of the mitochondria make them the prime target for treatments for majority of diseases and in particular of the cardiovascular system. The mitochondria are also considered to play an integral role in the manifestation of the cardiotoxic effects of compounds such as doxorubicin. The current project is designed to investigate the cardiotoxic effects of doxorubicin at tissue, cellular and protein level. In addition, it is investigated whether the inhibition of the mitochondrial permeability transition pore (mPTP) with cyclosporin A (CsA) or the inhibition of mitochondrial fission with the mitochondrial division inhibitor (mdivi-1) protects against the detrimental effects of doxorubicin on cardiac function. We also investigated whether co-treatment of doxorubicin with either CsA or mdivi-1 has any negative interaction with the cytotoxicity of doxorubicin against cancer cells. Langendorff results indicated that doxorubicin caused a time dependent reduction in the haemodynamic function of the heart as well as causing an increase in the infarct size to risk ratio in both naïve conditions and in conditions of ischaemia and reperfusion. Detrimental effects of doxorubicin on cardiac function were abrogated by co-treatment of doxorubicin with CsA or mdivi-1 in naïve conditions and in conditions of ischaemia and reperfusion. Cell viability data of isolated cardiac myocytes revealed that doxorubicin caused a concentration dependant decrease in the viability of neonatal cardiac myocytes as well as causing a reduction in the time taken to depolarisation and hypercontracture under sustained oxidative stress, all of which were prevented when co-treated with either CsA or mdivi-1. Doxorubicin significantly elevated the levels of p-Akt, p-Erk, p-Drp1 and p-p53. Co-treatment with CsA prevented the increase in the levels of p-Akt and p-Erk caused by doxorubicin in both naïve and IR condition whereas mdivi-1 prevented the increase in the levels of p-Erk, p-Drp1 and p-p53 and caused further increase in the levels of p-Akt. Using sinusoidal muscle length change during contraction and relaxation, it is demonstrated that doxorubicin caused a decrease in the power output, peak force and force during shorting. Detrimental effects of doxorubicin on work-loop contraction were abrogated when doxorubicin was co-administered with CsA. To conclude, results demonstrated that doxorubicin caused cardiotoxicity at tissue, cellular and protein level in both naïve conditions and in conditions of ischaemia and reperfusion injury. In addition, it is shown that the inhibition of mitochondrial permeability transition pore with CsA or the inhibition of the mitochondrial fission with mdivi-1 protect against doxorubicin-induced toxicity without affecting its anti-cancer properties.
APA, Harvard, Vancouver, ISO, and other styles
3

Bennett, Joanna. "Community psychiatric nurse practice in assessing side effects of antipsychotic drugs." Thesis, University of Hertfordshire, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.309696.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wu, Zimei, and n/a. "Formulation approaches to minimise injection site reactions of poorly soluble drugs." University of Otago. School of Pharmacy, 2006. http://adt.otago.ac.nz./public/adt-NZDU20070503.122315.

Full text
Abstract:
Purpose: The aim of this study was to investigate the usefulness of formulation approaches to minimise injection site reactions for poorly soluble drugs. The specific objectives were to modify the injection site reactions by identification of irritant components in the formulation and control of their release kinetics; and to gain understanding of formulation approaches to create a favourable microenvironment in the tissues allowing better tissue tolerance and drug absorption. Methods: Physicochemical properties of the model drug, ricobendazole (RBZ) were characterised using conventional methods. Three formulation approaches to minimise irritancy of the low pH RBZ solution were assessed. An in vitro method using 96-well microplates and a microtiter plate reader was used for detection of drug precipitation on dilution for formulation characterisation. Cellular damage by the formulations was investigated in L929 fibroblasts using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and lactate dehydrogenase (LDH) assays. Tissue tolerance and pharmacokinetics were simultaneously investigated after subcutaneous injection in sheep. A low pH RBZ solution was used as a reference formulation. Results: Preformulation studies showed that RBZ was practically insoluble in water and oils, and was slightly soluble in commonly used co-solvents. Solubility was slightly improved by complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD, K₁:₁ = 311 M⁻�) or a combination of low pH (> 2) with surfactants or co-solvents. A U-shaped pH-solubility profile in aqueous solutions indicated that RBZ is an ampholyte. pKa values measured by absorbance spectroscopy and pH solubility methods were 3.45 and 3.76 (basic) and 9.82 and 9.53 (acidic) respectively. The partition coefficient was 14.3 - 15.2 at pH 6 - 9 and less at higher or lower pH. In aqueous solutions, RBZ showed a V-shaped pH-degradation rate profile and was most stable at pH 4.8. Degradation pathways were identified as hydrolysis and oxidation. Three RBZ injectables (5%) were obtained by modification of the low pH RBZ solution; addition of 20% HP-β-CD, incorporation into a w/o emulsion, and a microemulsion (ME). On dilution with SPB, the onset time of drug precipitation was prolonged and the rate was reduced in the presence of HP-β-CD. The w/o emulsion had a low viscosity (< 60 mPa.s) and exhibited Newtonian flow. Drug release versus the square root of time was linear and the release rate could be adjusted by phase ratio and droplet size. Drug release was found to be by diffusion. A coarse emulsion layer appeared at the interface between the ME and buffer. Drug release from the ME was faster than from the emulsion and was linear with the square root of time. On titration into SPB, the three formulations showed controlling effects on the release of H₃O⁺ compared to the reference formulation. RBZ (0.1 mg/ml) was more toxic to L929 cells than the co-solvent propylene glycol (50 mg/ml). The formulations showed greater cytotoxicity than their vehicles in the order: ME > RBZ solution = emulsion > HP-β-CD. HP-β-CD and emulsion excipients showed little or no cytotoxicity. The MEs exhibited more toxicity in the LDH assay than in the MTS assay. A reversed phase HPLC assay for simultaneous determination of RBZ and its metabolite in sheep plasma using an isocratic system with UV detection was developed and used in the pharmacokinetic studies. Plasma samples were prepared by solid phase extraction. A suitable internal standard was selected by quantitative structure-retention relationships analysis. The composition of a ternary mobile phase was optimised with the assistance of multiple linear regression. The assays were linear over the concentration range 10 - 1000 ng/ml for both analytes (r > 0.999) with satisfactory inter-day and intra-day precision and accuracy (CV < 10%). The recoveries for all analytes were > 96%. A pilot study in sheep suggests that injection of the vehicles (the CD, emulsion and ME) caused virtually no pain on injection or site reactions. Both the reference formulation and its vehicle induced pain on injection and resulted in swollen tissues. Histology after two weeks showed granulation for the formulation, but not the vehicle. In contrast, animals showed virtually no injection site reactions with the ME and emulsion. The HP-β-CD formulation gave transient pain on injection but a two-fold increase in bioavailability compared with the reference. The emulsion produced sustained drug release and increased drug absorption. In the main study, the HP-β-CD vehicle showed good tissue compatibility. Irritation by the HP-β-CD formulation was attributed to the low pH. Cmax, tmax and AUC0-[infinity] for the reference formulation were 1.3 � 0.3 [mu]g/ml, 9.6 � 2.9 h and 36.7 � 9.2 [mu]g�h/ml respectively, while the corresponding data for the HP-β-CD formulation were 2.9 � 0.8 [mu]g/ml, 5.0 � 0.6 h and 54.5 � 15.3 [mu]g�h/ml respectively. The half-life following the injection of the HP-β-CD formulation (5.5 � 2.8 h) was shorter than that of the reference formulation (8.5 � 3.4 h). Conclusions: Injection site reactions may be minimised by identification of irritant components in a formulation and by controlling their release. Controlling the burst release of the poorly water soluble drug RBZ in a low pH solution could improve tissue tolerance and minimise post-injection precipitation, and hence increase drug bioavailability. In addition, HP-β-CD was a useful local injectable carrier which significantly enhanced the absorption of RBZ after subcutaneous injection in sheep.
APA, Harvard, Vancouver, ISO, and other styles
5

Khazaeinia, Tahereh. "Local and systemic gastrointestinal side effects of nonsteroidal anti-inflammatory drugs, NSAIDs." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0014/NQ59980.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lau, Phyllis Min-yu. "Adverse drug reactions in oncology." Monash University, Dept. of Pharmacy Practice, 2003. http://arrow.monash.edu.au/hdl/1959.1/5549.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Olsén, Lena. "Drugs in horses : pharmacokinetics and pharmacodynamics /." Uppsala : Dept. of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, 2007. http://epsilon.slu.se/200737.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gouws, Stephanus Andries. "The impact of hospital surveillance programmes on the incidence of adverse drug reaction reporting in a South African teaching hospital." Master's thesis, University of Cape Town, 1989. http://hdl.handle.net/11427/27186.

Full text
Abstract:
Post-marketing surveillance refers to any non-experimental or observational study, method, or monitoring strategy that is applied to obtain information on drug experience (primarily adverse) after a drug has been approved for clinical use. One of the major problems in post-marketing surveillance studies is the lack or under-reporting of drug experiences by health care professionals. This study was developed to describe the impact of three different prescription event monitoring programmes on the reporting of adverse drug reactions (ADR's) in the hospital situation. The intensive ADR monitoring programme and two voluntary ADR monitoring programmes which followed were conducted in the medical wards of an urban teaching and referral hospital. All patients admitted to the designated wards were monitored by a dedicated pharmacist in the intensive programme, ward pharmacists in the first voluntary programme and by medical and nursing staff in the second voluntary programme. The pharmacist monitored a cohort of patients prospectively in two medical wards for a period of three months. The patient's record was linked with any suspected ADR. All details, i.e. patient drug orders, characteristics and ADR description, were recorded and then reported. From 228 patients monitored, 25 cases have been reported. The impact of the intensive ADR monitoring programme was a reporting rate of 11 percent. Reports were received on ADR's of a particularly mild, common and pharmacologically predictable (type A) nature. The first voluntary ADR monitoring programme comprised the reporting of suspected AD R's and the recording of drug orders for the patients and the patient characteristics. The ward pharmacists monitored for suspected AD R's in all patients during their regular ward rounds. Six cases were reported in a population of 1506 patients monitored during the three months. The reports were mainly on moderate to severe suspected AD R's of pharmacologically unpredictable (type B) nature. The rate of reports received by the surveillance unit in this study was 4 reports per ward pharmacist per annum. The second voluntary ADR monitoring programme comprised the prospective monitoring of 1555 patients by medical and nursing staff during their stay at the designated medical wards during the three month period. Patients were monitored for any ADR and when an ADR was suspected, the patient characteristics and drug orders were recorded and reported to the surveillance unit. Ten cases were reported represented by six reports from doctors and four by sisters. The reporting rate was 2 reports per doctor in four years and 3 reports for each member of the nursing team in 5 years. Reports were mainly received on moderate to severe suspected ADR's of a pharmacologically unpredictable (type B) nature.
APA, Harvard, Vancouver, ISO, and other styles
9

O'Brien, Michelle University of Ballarat. "A study of multiple perspectives and knowledge in adverse drug reaction decision-making : Volume 1." University of Ballarat, 2004. http://archimedes.ballarat.edu.au:8080/vital/access/HandleResolver/1959.17/12769.

Full text
Abstract:
Injury and illness associated with drugs are major problems in Australia and around the world, despite significant developments in the area of adverse drug reaction (ADR) decision support technology. The aims of this thesis are: to investigate the ADR decision domain; to determine factors that may assist in the prevention, detection and management of ADRs; and, to inform the pre-requirements analysis phase of the development of decision support systems. An approach has been taken that permits open and grounded study of the decision environment. This approach can then be used to frame and inform the design of an ADR decision support system. Fifteen case studies that comprise self selected consumers, the treating medical practitioner/s and expert perspectives of a single instance of an ADR (fifteen in-depth consumer interviews, eight in-depth medical practitioner interviews and 30 expert written questionnaires), have been collected and analysed using a grounded theory approach, a symbolic interactionist theoretical framework and a social constructionist epistemology. The analysis was performed from three perspectives: individual case study analysis (all interviews for an instance of an ADR); group analysis (consumer, medical practitioner and expert views) and analysis combining the individual case studies and groups of data. Concepts, themes and theory have emerged from these data in the following areas: • the contribution of the differences in understanding of the core concepts within this domain, to misunderstandings between decision-makers; • the consumer as a diagnostic decision-maker in the ADR decision domain; • differential diagnostic strategies used by the consumers and medical practitioners; • complexities in the ADR decision domain that make diagnosis difficult; • the role of ADR information in consumer and medical practitioner decision-making; • decision types used by consumers and medical practitioners in the ADR decision domain; • resources used by consumers, medical practitioners and experts to inform their ADR decisions; • decision-making with partial knowledge of the consumer case history, drug behaviour and diseases; • the impact of suspected ADRs on consumers and on future decision-making; • medical practitioner/consumer decision-making models; and, • reasons for low ADR reporting and the impact on the development of new ADR knowledge. The results above suggest the following: • The ADR decision domain is more complex than the current ADR decision support focus and that broadening this focus may assist in providing a more complete and useful decision support solution. • Improving the prevention, detection and management of ADRs requires more than providing prescribers with up to date ADR information. Other important factors are sharing of information, awareness of the role of the consumer, a collaborative approach between the consumers and medical practitioners, and generation of new ADR knowledge. • A grounded theory analysis of case study data using the theoretical perspectives of social constructionism and symbolic interactionism provided insight into this domain from the perspectives of multiple decision-makers. This may be an approach that can be used by systems analysts to inform the requirements analysis phases of decision support within other domains. The results of this qualitative work are preliminary. Future work is required to confirm and expand these results.
Doctor of Philosophy
APA, Harvard, Vancouver, ISO, and other styles
10

O'Brien, Michelle. "A study of multiple perspectives and knowledge in adverse drug reaction decision-making : Volume 1." University of Ballarat, 2004. http://archimedes.ballarat.edu.au:8080/vital/access/HandleResolver/1959.17/14606.

Full text
Abstract:
Injury and illness associated with drugs are major problems in Australia and around the world, despite significant developments in the area of adverse drug reaction (ADR) decision support technology. The aims of this thesis are: to investigate the ADR decision domain; to determine factors that may assist in the prevention, detection and management of ADRs; and, to inform the pre-requirements analysis phase of the development of decision support systems. An approach has been taken that permits open and grounded study of the decision environment. This approach can then be used to frame and inform the design of an ADR decision support system. Fifteen case studies that comprise self selected consumers, the treating medical practitioner/s and expert perspectives of a single instance of an ADR (fifteen in-depth consumer interviews, eight in-depth medical practitioner interviews and 30 expert written questionnaires), have been collected and analysed using a grounded theory approach, a symbolic interactionist theoretical framework and a social constructionist epistemology. The analysis was performed from three perspectives: individual case study analysis (all interviews for an instance of an ADR); group analysis (consumer, medical practitioner and expert views) and analysis combining the individual case studies and groups of data. Concepts, themes and theory have emerged from these data in the following areas: • the contribution of the differences in understanding of the core concepts within this domain, to misunderstandings between decision-makers; • the consumer as a diagnostic decision-maker in the ADR decision domain; • differential diagnostic strategies used by the consumers and medical practitioners; • complexities in the ADR decision domain that make diagnosis difficult; • the role of ADR information in consumer and medical practitioner decision-making; • decision types used by consumers and medical practitioners in the ADR decision domain; • resources used by consumers, medical practitioners and experts to inform their ADR decisions; • decision-making with partial knowledge of the consumer case history, drug behaviour and diseases; • the impact of suspected ADRs on consumers and on future decision-making; • medical practitioner/consumer decision-making models; and, • reasons for low ADR reporting and the impact on the development of new ADR knowledge. The results above suggest the following: • The ADR decision domain is more complex than the current ADR decision support focus and that broadening this focus may assist in providing a more complete and useful decision support solution. • Improving the prevention, detection and management of ADRs requires more than providing prescribers with up to date ADR information. Other important factors are sharing of information, awareness of the role of the consumer, a collaborative approach between the consumers and medical practitioners, and generation of new ADR knowledge. • A grounded theory analysis of case study data using the theoretical perspectives of social constructionism and symbolic interactionism provided insight into this domain from the perspectives of multiple decision-makers. This may be an approach that can be used by systems analysts to inform the requirements analysis phases of decision support within other domains. The results of this qualitative work are preliminary. Future work is required to confirm and expand these results.
Doctor of Philosophy
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Side effects of drugs"

1

Cutaneous side effects of drugs. Philadelphia: Saunders, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Meyler's side effects of cariovascular drugs. Amsterdam: Elsevier Science, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

D, Teehan Michael, ed. Antipsychotics and their side effects. Cambridge: Cambridge University Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Aronson, J. K. Meyler's side effects of psychiatric drugs. Amsterdam: Elsevier, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Neurotoxic side effects of prescription drugs. Boston: Butterworth-Heinemann, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mathur, Leo K. Understanding the side effects of drugs. Vernon Hills, IL: Red Educational Services, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rainsford, K. D., and G. P. Velo, eds. Side-Effects of Anti-Inflammatory Drugs. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-010-9772-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rainsford, K. D., and G. P. Velo, eds. Side-Effects of Anti-Inflammatory Drugs. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-010-9775-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stern, Edward L. Prescription drugs and their side effects. 7th ed. New York, NY: Putnam's Sons, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

1926-, Griffith H. Winter, ed. Prescription drugs and their side effects. 7th ed. New York, NY: Body Press/Perigee, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Side effects of drugs"

1

de Groot, A. C. "Dermatological drugs, topical drugs and cosmetics." In Side Effects of Drugs Annual, 163–80. Elsevier, 1994. http://dx.doi.org/10.1016/s0378-6080(05)80259-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Othumpangat, Sreekumar, John D. Noti, and Sidhartha D. Ray. "Antiviral Drugs." In Side Effects of Drugs Annual, 329–48. Elsevier, 2015. http://dx.doi.org/10.1016/bs.seda.2015.05.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sandoval, Karin, and Ken Witt. "Gastrointestinal Drugs." In Side Effects of Drugs Annual, 433–59. Elsevier, 2015. http://dx.doi.org/10.1016/bs.seda.2015.05.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chue, P., and G. Baker. "Antipsychotic Drugs." In Side Effects of Drugs Annual, 63–83. Elsevier, 2015. http://dx.doi.org/10.1016/bs.seda.2015.07.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Onakpoya, Igho J. "Antihelminthic Drugs." In Side Effects of Drugs Annual, 367–81. Elsevier, 2015. http://dx.doi.org/10.1016/bs.seda.2015.07.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McManus, Dayna S. "Antifungal Drugs." In Side Effects of Drugs Annual, 307–19. Elsevier, 2015. http://dx.doi.org/10.1016/bs.seda.2015.07.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ahmed, Nazeer, Ashley Martinelli, and Catherine Kiruthi. "Antihypertensive Drugs." In Side Effects of Drugs Annual, 227–36. Elsevier, 2015. http://dx.doi.org/10.1016/bs.seda.2015.08.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Thurston, Scott, Gary L. Hite, Alyssa N. Petry, and Sidhartha D. Ray. "Antiprotozoal Drugs." In Side Effects of Drugs Annual, 321–27. Elsevier, 2015. http://dx.doi.org/10.1016/bs.seda.2015.08.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Smithson, Jonathan, and Philip B. Mitchell. "Antidepressant Drugs." In Side Effects of Drugs Annual, 11–19. Elsevier, 2016. http://dx.doi.org/10.1016/bs.seda.2016.07.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chue, P., and J. Chue. "Antipsychotic Drugs." In Side Effects of Drugs Annual, 35–54. Elsevier, 2016. http://dx.doi.org/10.1016/bs.seda.2016.08.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Side effects of drugs"

1

Agrebi, Soumaya, Soumaya Ben Saad, Chaima Habouria, Hafaoua Daghfous, and Fatma Tritar. "Tolerance and side effects of second line anti tubercular drugs." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Alhajj, Sleiman, and Salih Gencer. "Investigating Side Effects of Existing Drugs Used in Covid-19 Treatment." In 2020 IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining (ASONAM). IEEE, 2020. http://dx.doi.org/10.1109/asonam49781.2020.9381474.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

González-Díaz, Humberto, Maykel Cruz-Monteagudo, Miguel Cabrera-Pérez, Reinaldo Molina-Ruiz, and Yunierkis Pérez-Castillo. "Unify Markov model for Rational Design and Synthesis of More Safe Drugs. Predicting Multiple Drugs Side Effects." In The 9th International Electronic Conference on Synthetic Organic Chemistry. Basel, Switzerland: MDPI, 2005. http://dx.doi.org/10.3390/ecsoc-9-01658.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hwang, Sohee, Jungrim Kim, and Sanghyun Park. "Recommend alternative drugs to minimize side-effect using generic name of drug." In EDB: 2016 International Conference on Emerging Databases. New York, NY, USA: ACM, 2016. http://dx.doi.org/10.1145/3007818.3007846.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cooper, Daniel B., and Pavlos P. Vlachos. "Parametric Investigation of Magnetic Particle Transport for Targeted Drug Delivery Applications." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53889.

Full text
Abstract:
In recent years, there has been significant clinical and research interest in magnetic drug targeting (MDT). MDT allows the targeted delivery of drugs only to the affected sites, alleviating the rest of the body from the potential toxic or other side effects of the drug. The underlying concept of MDT is to attach drugs to small magnetic particles which can then be manipulated by a magnetic field designed to attract the drug carrying particles to the target site [1]. This will lead to increasing localized accumulation of the drug at the target site. MDT can have great implications on pharmaceutical treatments, ranging from oncology to cardiology and beyond [2, 3].
APA, Harvard, Vancouver, ISO, and other styles
6

Balachandran, Ram K., and Victor H. Barocas. "Effect of Active Transport and Loss to Choroidal Blood Flow on Transscleral Drug Delivery to the Posterior Eye." In ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-175366.

Full text
Abstract:
Delivering drugs to the posterior eye has been a challenge for many years. Systemic delivery of drugs is not a viable option because the eye does not receive enough blood supply, because of its small size, for the drug delivery process to be effective. Topical delivery in the form of eye drops is also ineffective in generating therapeutic concentrations in the posterior eye, because of the resistance offered by the corneal epithelium to the transport of drugs, and rapid elimination due to aqueous humor flow and tear dilution. Intravitreal delivery of drugs through implants and injections has been associated with serious side effects like endophthalmitis, hemorrhage, and retinal detachment. In recent years, transcleral delivery of drugs has received attention due to the relatively high permeability of the sclera.
APA, Harvard, Vancouver, ISO, and other styles
7

Bozsak, Franz, Jean-Marc Chomaz, and Abdul I. Barakat. "Dynamics of Arterial Wall Transport for Small Hydrophobic Drugs." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80541.

Full text
Abstract:
Drugs used in drug-eluting stents (DES) to inhibit proliferation of smooth muscle cells (SMCs) also limit re-endothelialization at the site of stent implantation [1]. Thus, treated patients face an increased risk of late-stent thrombosis. Avoiding this adverse side effect represents one of the major challenges in the design of next-generation DES.
APA, Harvard, Vancouver, ISO, and other styles
8

Curino, Carlo A., Yuanyuan Jia, Bruce Lambert, Patricia M. West, and Clement Yu. "Mining officially unrecognized side effects of drugs by combining web search and machine learning." In the 14th ACM international conference. New York, New York, USA: ACM Press, 2005. http://dx.doi.org/10.1145/1099554.1099670.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lee, Sejoon, Min Song, and Doheon Lee. "Discovering biological processes and side effects relationship using the process-drug-side effect network." In the ACM fourth international workshop. New York, New York, USA: ACM Press, 2010. http://dx.doi.org/10.1145/1871871.1871878.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Madhav, Bhumika, Aparna Iyer, and T. K. Jayalakshmi. "Side effect profile of 2ndline drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2708.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Side effects of drugs"

1

Pearce, Oliver, and Mohga Kamal-Yanni. Harmful Side Effects: How drug companies undermine global health. Oxfam GB, September 2018. http://dx.doi.org/10.21201/2018.3217.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Repository, Science. Hold the Prescription and Try These Natural Antibiotics Instead. Science Repository OÜ, December 2020. http://dx.doi.org/10.31487/sr.blog.20.

Full text
Abstract:
The significance of natural antibiotics lies in the fact that they are effective against infections without causing enough side effects. Substitution of prescription drugs with these can completely eradicate the adverse side effects of antibiotics.
APA, Harvard, Vancouver, ISO, and other styles
3

Johnson, Corey, Colton James, Sarah Traughber, and Charles Walker. Postoperative Nausea and Vomiting Implications in Neostigmine versus Sugammadex. University of Tennessee Health Science Center, July 2021. http://dx.doi.org/10.21007/con.dnp.2021.0005.

Full text
Abstract:
Purpose/Background: Postoperative nausea and vomiting (PONV) is a frequent complaint in the postoperative period, which can delay discharge, result in readmission, and increase cost for patients and facilities. Inducing paralysis is common in anesthesia, as is utilizing the drugs neostigmine and sugammadex as reversal agents for non-depolarizing neuromuscular blockers. Many studies are available that compare these two drugs to determine if neostigmine increases the risk of PONV over sugammadex. Sugammadex has a more favorable pharmacologic profile and may improve patient outcomes by reducing PONV. Methods: This review included screening a total of 39 studies and peer-reviewed articles that looked at patients undergoing general anesthesia who received non-depolarizing neuromuscular blockers requiring either neostigmine or sugammadex for reversal, along with their respective PONV rates. 8 articles were included, while 31 articles were removed based on our exclusion criteria. These were published between 2014 and 2020 exclusively. The key words used were “neostigmine”, “sugammadex”, “PONV”, along with combinations “paralytic reversal agents and PONV”. This search was performed on the scholarly database MEDLINE. The data items were PONV rates in neostigmine group, PONV rates in sugammadex group, incidence of postoperative analgesic consumption in neostigmine group, and incidence of postoperative analgesic consumption in sugammadex group. Results: Despite numerical differences being noted in the incidence of PONV with sugammadex over reversal with neostigmine, there did not appear to be any statistically significant data in the multiple peer-reviewed trials included in our review, for not one of the 8 studies concluded that there was a higher incidence of PONV in one drug or the other of an y clinical relevance. Although the side-effect profile tended to be better in the sugammadex group than neostigmine in areas other than PONV, there was not sufficient evidence to conclude that one drug was superior to the other in causing a direct reduction of PONV. Implications for Nursing Practice: There were variable but slight differences noted between both drug groups in PONV rates, but it remained that none of the studies determined it was statically significant or clinically conclusive. This review did, however, note other advantages to sugammadex over neostigmine, including its pharmacologic profile of more efficiently reversing non-depolarizing neuromuscular blocking drugs and its more favorable pharmacokinetics. This lack of statistically significant evidence found within these studies consequentially does not support pharmacologic decision-making of one drug in favor of the other for reducing PONV; therefore, PONV alone is not a sufficient rationale for a provider to justify using one reversal over another at the current time until further research proves otherwise.
APA, Harvard, Vancouver, ISO, and other styles
4

Broufas, G. D., and R. J. M. Meijer. Pesticides side-effects. BioGreenhouse, 2016. http://dx.doi.org/10.18174/373602.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Miller, Gilbert J. Original Long War: Supply-Side Strategy in the War on Drugs. Fort Belvoir, VA: Defense Technical Information Center, March 2008. http://dx.doi.org/10.21236/ada479108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Degener, J. Sieve Extension: Copying Without Side Effects. RFC Editor, October 2004. http://dx.doi.org/10.17487/rfc3894.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Baqaee, David, Emmanuel Farhi, and Kunal Sangani. The Supply-Side Effects of Monetary Policy. Cambridge, MA: National Bureau of Economic Research, January 2021. http://dx.doi.org/10.3386/w28345.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Berndt, Ernst, Robert Pindyck, and Pierre Azoulay. Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs. Cambridge, MA: National Bureau of Economic Research, March 1999. http://dx.doi.org/10.3386/w7024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tsoukas, Constantine D. Effects of Immunomodulatory Drugs on T Lymphocyte Activation and Function. Fort Belvoir, VA: Defense Technical Information Center, November 1989. http://dx.doi.org/10.21236/ada225770.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wang, G., T. L. Rhodes, W. A. Peebles, R. W. Harvey, and R. V. Budny. Refractive and Relativistic Effects on ITER Low Field Side Reflectometer Design. Office of Scientific and Technical Information (OSTI), June 2010. http://dx.doi.org/10.2172/981716.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Side effects of drugs' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography